TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2103060
Drug: Succinylcholine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.0 mg.kg‐1
Study: 27909950
Drug: sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib 400 mg BID
Study: 27909950
Drug: corticosteroid ointment
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: corticosteroid ointment
Study: 23662517
Drug: Abdominal cross
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abdominal cross section space (ACSB) blockade with non-opioid analgesics
Study: 12070058
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 500 microg twice daily via a dry powder inhaler
Study: 10468683
Drug: ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine bismuth citrate (RBC) 400 mg with clarithromycin 500 mg
Study: 10468683
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg with clarithromycin 500 mg
Study: 2270564
Drug: 0.5% sanguinarine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% sanguinarine gel
Study: 2270564
Drug: 0.05% and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% and 0.5% sanguinarine gel
Study: 7214806
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravenous glucagon
Study: 27837101
Drug: Exercise (6-month,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise (6-month, twice weekly programme: 30 min aerobic and 30 min resistance)
Study: 27837101
Drug: Handwriting (6-month,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handwriting (6-month, twice weekly programme at home)
Study: 23210726
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (300 mg single dose)
Study: 23210726
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg twice daily for 3 days)
Study: 21537018
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of oritavancin (200 mg for 3 to 7 days)
Study: 21537018
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oritavancin (1,200 mg)
Study: 21537018
Drug: Infrequent dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrequent dose of oritavancin (800 mg with an option for an additional 400 mg on day 5)
Study: 21537018
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of oritavancin (200 mg) in MRSA patients
Study: 21537018
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oritavancin (1,200 mg) in MRSA patients
Study: 21537018
Drug: Infrequent dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrequent dose of oritavancin (800 mg with an option for an additional 400 mg on day 5) in MRSA patients
Study: 19299779
Drug: Remifentanil (infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (infusion rate 0.014 +/- 0.011 microg x kg(‐1) x min(‐1))
Study: 15293769
Drug: Newer antidepressant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antidepressant agents
Study: 15293769
Drug: Older antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older antidepressant agents
Study: 9252005
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose alfentanil (100 microg kg(‐1) induction, 1‐2 microg kg(‐1) min(‐1) infusion)
Study: 9252005
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alfentanil (30 microg kg(‐1) induction, 10‐20 microg kg(‐1) bolus every hour)
Study: 19333167
Drug: Gabapentin ER
Normalized name: gabapentin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin ER once daily (1800 mg PM)
Study: 19333167
Drug: Gabapentin ER
Normalized name: gabapentin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin ER twice daily (600 mg AM, 1200 mg PM)
Study: 17709449
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 microg selenium, and 20 mg zinc)
Study: 7601181
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg bds)
Study: 7601181
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg tds)
Study: 28384800
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (200,000 IU initial dose, followed by 100,000 IU monthly)
Study: 18285548
Drug: Maribavir 100
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir 100 mg twice daily
Study: 12027147
Drug: Calcium-vitamin D
Normalized name: Calcium-Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-vitamin D (CaD) supplementation (calcium carbonate 500 mg, citric acid 2.175 gr, cholecalciferol 200 IU)
Study: 12027147
Drug: Calcium (Ca)
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (Ca) supplementation (calcium gluconolactate and carbonate 500 mg)
Study: 7572012
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of oral tizanidine
Study: 7572012
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of oral tizanidine
Study: 2144295
Drug: DHEA 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 1600 mg/day (in four divided doses) for 28 days
Study: 377968
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of norgestimate (0.125 mg) and ethinyl estradiol (0.035 mg)
Study: 377968
Drug: Various dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various dosage combinations of norgestimate and ethinyl estradiol
Study: 31605392
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% 5 mL
Study: 31605392
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% 15 mL
Study: 31605392
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% 20 mL
Study: 31605392
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% 30 mL
Study: 23332872
Drug: TKI re-treatment
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKI re-treatment (sunitinib, sorafenib, dovitinib) after everolimus
Study: 11407727
Drug: Troglitazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (200 mg bid)
Study: 11407727
Drug: Glibenclamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (2.5 mg daily)
Study: 9587532
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg per day for 4 weeks
Study: 8460390
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation (4g Mg granulate verum, 6.7 mmol Mg aspartate)
Study: 23979789
Drug: Dietary energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary energy density (kcal/g)
Study: 21863204
Drug: Psychological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatments (defined as interventions involving verbal communication between a therapist and a patient)
Study: 17655736
Drug: Bed rest
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bed rest and concurrent exercise training countermeasure (BRE, n = 8)
Study: 11716384
Drug: Posterior-stabilized AMK
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior-stabilized AMK total knee implants
Study: 11716384
Drug: Cruciate-retaining AMK
Normalized name: Gentiana cruciata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cruciate-retaining AMK total knee implants
Study: 2565729
Drug: Adrenaline 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 0.3 mg subcutaneously
Study: 2565729
Drug: Adrenaline 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 0.3 mg subcutaneously preceded by ICI 118,551 5 mg orally
Study: 2565729
Drug: Salbutamol 8
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 8 mg orally
Study: 21257263
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of ibuprofen 200mg/paracetamol 500mg
Study: 21257263
Drug: 2 tablets
Normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of ibuprofen 200mg/paracetamol 500mg
Study: 21257263
Drug: 2 tablets
Normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of ibuprofen 200mg/codeine 12.8mg
Study: 21257263
Drug: 2 tablets
Normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of paracetamol 500mg/codeine 15mg
Study: 19320234
Drug: BILB 1941
Normalized name: Bilberry
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILB 1941 60 mg
Study: 19320234
Drug: BILB 1941
Normalized name: Bilberry
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILB 1941 80 mg
Study: 19320234
Drug: BILB 1941
Normalized name: Bilberry
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILB 1941 100 mg
Study: 19320234
Drug: BILB 1941
Normalized name: Bilberry
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILB 1941 150 mg
Study: 19320234
Drug: BILB 1941
Normalized name: Bilberry
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILB 1941 200 mg
Study: 19320234
Drug: BILB 1941
Normalized name: Bilberry
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILB 1941 300 mg
Study: 19320234
Drug: BILB 1941
Normalized name: Bilberry
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILB 1941 450 mg
Study: 9333147
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) plus hydroxyurea (HU) combination therapy
Study: 8226485
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 2 x 2.5 mg/kg x day-1
Study: 3801360
Drug: Norethisterone 5
Normalized name: Norethisterone 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone 5 mg/day
Study: 3801360
Drug: Norethisterone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone 2.5 mg/day
Study: 23540683
Drug: l-lactate infusion
Normalized name: L-lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-lactate infusion (target concentration 3 mmol/L)
Study: 7893268
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose powder inhaler (MDPI; Easyhaler)
Study: 8177971
Drug: Conventional metered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional metered dose inhaler (MDI)
Study: 2688081
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium retard 100 mg
Study: 30051975
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg LY2495655 plus placebo
Study: 30051975
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg LY2495655 plus placebo
Study: 30051975
Drug: LY2495655 (either
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2495655 (either dose)
Study: 27708124
Drug: Cherry Crush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cherry Crush (CC), Piña Colada (PC), Peach Schnapps (PS)
Study: 24737415
Drug: Adjuvant imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant imatinib 400 mg/day for 12 months
Study: 24737415
Drug: Adjuvant imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant imatinib 400 mg/day for 36 months
Study: 18675959
Drug: GnRHa/chemotherapy cotreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa/chemotherapy cotreatment
Study: 18065071
Drug: Sequential practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential practice trials with short movement goal
Study: 18065071
Drug: Sequential practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential practice trials with long movement goal
Study: 18065071
Drug: Separate planning
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate planning of sequential aiming movements
Study: 15736608
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg or 400 mg of modafinil
Study: 8732145
Drug: Chinese integrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese integrated medicine (CIM)
Study: 413493
Drug: Nebulized sodium
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized sodium cromoglycate solution
Study: 28430159
Drug: Low-molecular-weight fucoidan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight fucoidan (LMF) as a supplemental therapy to chemotarget agents
Study: 28430159
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (chemotarget agents only)
Study: 17934385
Drug: Careful selection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Careful selection of medications and routine screening for cardiovascular risk factors
Study: 11408152
Drug: Intelisite capsule
Normalized name: AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 80 mg in 1 mL TOPICAL CREAM [Intensite Creme Lustre Day SPF 30 US]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intelisite capsule
Study: 9562581
Drug: Toxic effects
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toxic effects of therapy
Study: 7092136
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of metronidazole
Study: 28993069
Drug: Combination A
Normalized name: SUNFLOWER OIL 7.92 g in 14 g TOPICAL STICK [OrgaPlus Super Care Balm for combination and oi ly skin type 14g]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination A (silicone-hydrogel CLs)
Study: 28993069
Drug: Combination B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination B (silicone-hydrogel CLs)
Study: 25775634
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied to a representative plaque for 9 months
Study: 15962065
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of ketoprofen 100 mg (Group C)
Study: 15962065
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of tenoxicam 40 mg (Group T)
Study: 15962065
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of physiological serum 0.9% (Group F)
Study: 14756017
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical training (daily exercise program for 21 +/- 10 days)
Study: 10477986
Drug: Pain‐Free (oxalate‐containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain‐Free (oxalate‐containing pre‐polymerized resin suspension)
Study: 10477986
Drug: DentinBloc (0.7%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DentinBloc (0.7% fluoride solution)
Study: 3834830
Drug: Suppositories containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppositories containing sodium salicylate and Brij 35
Study: 3834830
Drug: Suppositories without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suppositories without adjuvants
Study: 3834830
Drug: Suppositories (general)
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppositories (general)
Study: 31578173
Drug: Apalutamide (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide (four 60 mg tablets, once daily)
Study: 24383843
Drug: imatinib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: imatinib 800 mg daily (IM800)
Study: 24383843
Drug: imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: imatinib 400 mg daily (IM400)
Study: 26428486
Drug: Donor lymphocyte
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor lymphocyte infusions
Study: 16163089
Drug: Topical negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical negative-pressure therapy with no interface dressing
Study: 16163089
Drug: Topical negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical negative-pressure therapy with Vaseline-impregnated gauze
Study: 16163089
Drug: Topical negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical negative-pressure therapy with nonadherent silicone dressing
Study: 16163089
Drug: Topical negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical negative-pressure therapy with mylar polyester film dressing
Study: 12393106
Drug: Warfarin prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prophylaxis and epidural analgesia
Study: 1874490
Drug: Chenodiol therapy
Normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodiol therapy
Study: 1874490
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (similar chenodiol doses, no liver injury)
Study: 23474008
Drug: Far infrared
Normalized name: Menthol/Methyl Salicylate 3%-0.5% Topical application Patch, Extended Release [GOLDEN SUNSHINE FAR INFRARED HOT HERBAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Far infrared therapy (40 minutes, 3 times weekly for a year)
Study: 23474008
Drug: Far infrared
Normalized name: Menthol/Methyl Salicylate 3%-0.5% Topical application Patch, Extended Release [GOLDEN SUNSHINE FAR INFRARED HOT HERBAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Far infrared therapy
Study: 21357380
Drug: High isoflavone
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High isoflavone intake (>16.3 mg isoflavones)
Study: 9973149
Drug: Amitriptyline (AMI;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (AMI; 25-37.5 mg)
Study: 9973149
Drug: Moclobemide (MOCLO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (MOCLO; 450-600 mg)
Study: 7977094
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose t-PA
Study: 7977094
Drug: Accelerated dose
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated dose t-PA
Study: 2908486
Drug: Control saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control saline solution
Study: 2908486
Drug: Histamine: aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine: aqueous solution (Hsol)
Study: 30101416
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine (CHX) solution
Study: 23951692
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 microg/kg over 10 minutes at anesthesia induction, followed by 0.4 to 0.8 microg/kg per hour infusion during maintenance
Study: 23951692
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 microg/kg over 1 minute at anesthesia induction, followed by 0.2 to 0.4 microg/kg per minute infusion during maintenance
Study: 17967217
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (20 mg daily)
Study: 16004022
Drug: Ciclopirox nail
Normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox nail lacquer once daily for 48 weeks plus 4 weeks of terbinafine 250 mg/day, followed by 4 weeks of rest (no terbinafine), then another 4 weeks of terbinafine 250 mg/day (PLs)
Study: 16004022
Drug: Ciclopirox nail
Normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox nail lacquer once daily for 48 weeks plus terbinafine 250 mg/day for 12 weeks (PL12)
Study: 16004022
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/day for 12 weeks (L12)
Study: 9892253
Drug: Glycine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine (0.8 g/kg per day)
Study: 9050688
Drug: Goserelin 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.75 mg
Study: 1931396
Drug: Clonidine 2
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 2 micrograms kg‐1 i.v. administered over 20 min
Study: 399527
Drug: Inhaled prostacyclin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled prostacyclin (PGI2)
Study: 31001633
Drug: 15/50 VLP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15/50 VLP vaccine formulation (15 µg of GI.1 and 50 µg of GII.4c VLPs)
Study: 31001633
Drug: 50/50 VLP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/50 VLP vaccine formulation (50 µg of GI.1 and 50 µg of GII.4c VLPs)